A case report of metformin-associated lactic acidosis.
Mohammed TahaAyman AzharyNooh Mohamed HajhamedWaleed Azhary Sir AlkhatimAbdullah M BakheitAbdallah Elssir AhmedPublished in: Clinical case reports (2024)
Metformin (MTF) is commonly prescribed as a first-line treatment for diabetes, effectively preventing microvascular and macrovascular complications. However, metformin-associated lactic acidosis is a rare yet severe complication, associated with a mortality rate of up to 50%. We encountered a case involving a 73-year-old woman with type 2 diabetes, mental illness, and hypothyroidism, who developed life-threatening lactic acidosis while on metformin therapy. Upon presenting to the emergency department with complaints of weakness, nausea, and decreased urination for 5 days, she also reported abdominal pain and shortness of breath. Hypotension was noted with a blood pressure of 80/50 mmHg. Initial laboratory results revealed severe acidosis, prompting discontinuation of MTF. Despite resuscitation efforts and vasopressor therapy, severe acidemia persisted, leading to the initiation of renal replacement therapy. Following treatment with continuous renal replacement therapy, her acidemia resolved, and she was discharged from the hospital on the sixth day without complications, with normal kidney function.
Keyphrases
- mental illness
- emergency department
- blood pressure
- abdominal pain
- acute kidney injury
- early onset
- risk factors
- type diabetes
- mental health
- cardiovascular disease
- cardiac arrest
- healthcare
- stem cells
- replacement therapy
- cardiovascular events
- quality improvement
- hypertensive patients
- adipose tissue
- insulin resistance
- case report
- skeletal muscle
- cardiopulmonary resuscitation
- blood glucose
- cell therapy
- electronic health record